{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:50:13Z","timestamp":1791942613709,"version":"4.3.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Psycho-dermatology is an evolving speciality of psychosomatic medicine where psychological factors play a role in initiating and\/or exacerbating the dermatological conditions. Dermatologists should be well versed with the basic pharmacotherapy of psycho-cutaneous disorders and work in close liaison with the psychiatrists when it comes to the holistic management of the same. The review has been divided into two parts, with part 1 consisting of anti-depressants and mood stabilisers and part 2 consisting of anti-psychotics, anxiolytics, and sedative-hypnotic agents used in psycho-dermatology. This comprehensive review focusses on the various psychotropic drugs which are of paramount significance to the dermatologists. The knowledge of these drugs will lead to the pertinent treatment of the psychiatric dermatoses, which has been a less explored territory in the arena of dermatology. Within the realm of psycho-dermatology, a diverse array of anti-depressants is utilised to address psychiatric dermatoses. These include selective serotonin reuptake inhibitors like citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, alongside selective serotonin norepinephrine reuptake inhibitors such as venlafaxine, desvenlafaxine, and duloxetine. Additionally, norepinephrine dopamine reuptake inhibitors like bupropion; tricyclic antidepressants including doxepin, amitriptyline, imipramine, and clomipramine; and tetracyclic antidepressants like mirtazapine are commonly employed. Supplementary medications like anti-convulsants (e.g., gabapentin and pregabalin) further enrich the therapeutic landscape in psycho-dermatology. The approach to treatment in psycho-dermatology is meticulous, starting with a precise psychiatric diagnosis and followed by tailored drug interventions. Factors such as individual response, side-effect profiles, potential drug interactions, and concurrent medical conditions guide the selection and titration of medications. Typically, treatment initiates at conservative doses, with adjustments made based on patient progress and tolerability. This comprehensive review not only illuminates the psycho-cutaneous indications of these medications including in patients with co-morbidties but also underscores the imperative of vigilant monitoring for adverse effects and its management. This systematic review aimed to evaluate the use of psychotropic medications, including antidepressants and mood stabilizers, in dermatology. A comprehensive search of PubMed Central was conducted for studies published between 1986 and 2023, focusing on meta-analyses, reviews, and systematic reviews. After screening 2287 records, 26 studies met the inclusion criteria. The findings underscore the potential role of psychotropic drugs in managing dermatological conditions, highlighting the need for further research to strengthen the evidence base in psycho-dermatology.<\/jats:p>","DOI":"10.4103\/ijd.ijd_792_23","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T02:01:55Z","timestamp":1735610515000},"page":"23-37","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Psychotropic Drugs in Dermatology Part 1: Anti-depressants and Mood Stabilisers"],"prefix":"10.4103","volume":"70","author":[{"given":"Varsha L.","family":"Kenkare","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Venereology and Leprosy, Dr. Surya\u2019s Skin Clinic, Sainikpuri, Secunderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Madke","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Sawangi Meghe, Wardha, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Choudhary","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, Hindu Rao Hospital, North Delhi Municipal Corporation Medical College, Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiti","family":"Bose","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprosy, City Hospital, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"R2-20250328","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/archderm.134.11.1431","article-title":"The neuro-immunocutaneous-endocrine network:Relationship of mind and skin","volume":"134","author":"O'Sullivan","year":"1998","journal-title":"Arch Dermatol"},{"key":"R3-20250328","doi-asserted-by":"crossref","first-page":"e13385","DOI":"10.1111\/dth.13385","article-title":"Psychotropic drugs in dermatology:A dermatologist's approach and choice of medications","volume":"33","author":"Jafferany","year":"2020","journal-title":"Dermatol Ther"},{"key":"R4-20250328","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S1085-5629(03)00045-2","article-title":"Psychocutaneous drug therapy","volume":"22","author":"Lee","year":"2003","journal-title":"Semin Cutan Med Surg"},{"key":"R5-20250328","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1529-8019.2008.00172.x","article-title":"Psychopharmacology in dermatology","volume":"21","author":"Lee","year":"2008","journal-title":"Dermatol Ther"},{"key":"R7-20250328","doi-asserted-by":"crossref","first-page":"18169","DOI":"10.5070\/D3195018169","article-title":"Psychopharmacological therapies in dermatology","volume":"19","author":"Wong","year":"2013","journal-title":"Dermatol Online J"},{"key":"R8-20250328","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1046\/j.1468-3083.2001.00278.x","article-title":"The use of antidepressant drugs in dermatology","volume":"15","author":"Gupta","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R9-20250328","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/idoj.IDOJ_330_19","article-title":"Update on pharmacotherapy in psychodermatological disorders","volume":"11","author":"Shenoi","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"R11-20250328","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.clindermatol.2018.08.012","article-title":"Use of psychotropic drugs in the dermatology patient:When to start and stop?","volume":"36","author":"Shah","year":"2018","journal-title":"Clin Dermatol"},{"key":"R12-20250328","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jaad.2016.11.021","article-title":"Psychocutaneous disease:Pharmacotherapy and psychotherapy","volume":"76","author":"Kuhn","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R13-20250328","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0733-8635(05)70222-9","article-title":"The use of psychotropic drugs in dermatology","volume":"18","author":"Gupta","year":"2000","journal-title":"Dermatol Clin"},{"key":"R14-20250328","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.det.2005.05.015","article-title":"Psychopharmacologic therapies in dermatology:An update","volume":"23","author":"Lee","year":"2005","journal-title":"Dermatol Clin"},{"key":"R15-20250328","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1610-0387.2007.06398.x","article-title":"Psychopharmacological treatment of dermatological patients--When simply talking does not help","volume":"5","author":"Harth","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"R16-20250328","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.clindermatol.2018.08.005","article-title":"Use of antiepileptic mood stabilizers in dermatology","volume":"36","author":"Gupta","year":"2018","journal-title":"Clin Dermatol"},{"key":"R17-20250328","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0190-9622(96)90284-4","article-title":"Psychodermatology:An update","volume":"34","author":"Gupta","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R18-20250328","doi-asserted-by":"crossref","first-page":"e13557","DOI":"10.1111\/dth.13557","article-title":"Psychopharmacology in dermatology:Treatment of primary psychiatric conditions in dermatology","volume":"33","author":"Torales","year":"2020","journal-title":"Dermatol Ther"},{"key":"R19-20250328","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/12034754231155888","article-title":"Pharmacological interventions for primary psychodermatologic disorders:An evidence mapping and appraisal of randomized controlled trials","volume":"27","author":"Turk","year":"2023","journal-title":"J Cutan Med Surg"},{"key":"R20-20250328","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.abd.2019.12.002","article-title":"Use of psychiatric drugs in dermatology","volume":"95","author":"Weber","year":"2020","journal-title":"An Bras Dermatol"},{"key":"R21-20250328","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2310\/7750.2008.07062","article-title":"Psychopharmacology in psychodermatology","volume":"12","author":"Shukla","year":"2008","journal-title":"J Cutan Med Surg"},{"key":"R22-20250328","doi-asserted-by":"crossref","first-page":"60","DOI":"10.25259\/CSDM_60_2021","article-title":"Selection of psychotropics in dermatologic practice","volume":"1","author":"Menon","year":"2021","journal-title":"CosmoDerma"},{"key":"R24-20250328","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0190-9622(86)70081-9","article-title":"Psychotropic drugs in dermatology. A review and guidelines for use","volume":"14","author":"Gupta","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"R25-20250328","doi-asserted-by":"crossref","first-page":"409","DOI":"10.31887\/DCNS.2008.10.4\/kkelly","article-title":"Toward achieving optimal response:Understanding and managing antidepressant side effects","volume":"10","author":"Kelly","year":"2008","journal-title":"Dialogues Clin Neurosci"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_792_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:02Z","timestamp":1786724702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_792_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_792_23","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"2023-08-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}